Works matching IS 01676997 AND DT 2013 AND VI 31 AND IP 2

Results: 31

Inhibition of topoisomerase II α activity and induction of apoptosis in mammalian cells by semi-synthetic andrographolide analogues.

Published in:

2013

By:

Nateewattana, Jintapat;
Saeeng, Rungnapha;
Kasemsook, Sakkasem;
Suksen, Kanoknetr;
Dutta, Suman;
Jariyawat, Surawat;
Chairoungdua, Arthit;
Suksamrarn, Apichart;
Piyachaturawat, Pawinee

Publication type:

Journal Article

Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Published in:

Investigational New Drugs, 2013, v. 31, n. 2, p. 417, doi. 10.1007/s10637-012-9861-3

By:

Seiwert, Tanguy;
Sarantopoulos, John;
Kallender, Howard;
McCallum, Stewart;
Keer, Harold;
Blumenschein, George

Publication type:

Article

Differences in drug approval processes of 3 regulatory agencies: a case study of gemtuzumab ozogamicin.

Published in:

Investigational New Drugs, 2013, v. 31, n. 2, p. 473, doi. 10.1007/s10637-012-9877-8

By:

Tanimoto, Tetsuya;
Tsubokura, Masaharu;
Mori, Jinichi;
Pietrek, Monika;
Ono, Shunsuke;
Kami, Masahiro

Publication type:

Article

A Phase I trial of the kinesin spindle protein (Eg5) inhibitor AZD4877 in patients with solid and lymphoid malignancies.

Published in:

Investigational New Drugs, 2013, v. 31, n. 2, p. 355, doi. 10.1007/s10637-012-9821-y

By:

Gerecitano, John;
Stephenson, Joe;
Lewis, Nancy;
Osmukhina, Anna;
Li, Jianguo;
Wu, Kaida;
You, Zhiping;
Huszar, Dennis;
Skolnik, Jeffrey;
Schwartz, Gary

Publication type:

Article

The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258.

Published in:

Investigational New Drugs, 2013, v. 31, n. 2, p. 265, doi. 10.1007/s10637-012-9851-5

By:

Vallo, Stefan;
Mani, Jens;
Stastny, Matthias;
Makarević, Jasmina;
Juengel, Eva;
Tsaur, Igor;
Bartsch, Georg;
Haferkamp, Axel;
Blaheta, Roman

Publication type:

Article

Unexpected renal toxicity associated with SGX523, a small molecule inhibitor of MET.

Published in:

Investigational New Drugs, 2013, v. 31, n. 2, p. 363, doi. 10.1007/s10637-012-9823-9

By:

Infante, Jeffrey;
Rugg, Terence;
Gordon, Michael;
Rooney, Isabelle;
Rosen, Lee;
Zeh, Karin;
Liu, Raymond;
Burris, Howard;
Ramanathan, Ramesh

Publication type:

Article

Enhanced killing of cervical cancer cells by combinations of methyl jasmonate with cisplatin, X or alpha radiation.

Published in:

Investigational New Drugs, 2013, v. 31, n. 2, p. 333, doi. 10.1007/s10637-012-9870-2

By:

Milrot, Elad;
Jackman, Anna;
Flescher, Eliezer;
Gonen, Pinhas;
Kelson, Itzhak;
Keisari, Yona;
Sherman, Levana

Publication type:

Article

A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer.

Published in:

Investigational New Drugs, 2013, v. 31, n. 2, p. 390, doi. 10.1007/s10637-012-9830-x

By:

Gómez-Martín, C.;
Salazar, R.;
Montagut, C.;
Gil-Martín, M.;
Núñez, J.;
Puig, M.;
Lin, X.;
Khosravan, R.;
Tursi, J.;
Lechuga, M.;
Bellmunt, J.

Publication type:

Article

Mechanisms of acquired resistance to insulin-like growth factor 1 receptor inhibitor in MCF-7 breast cancer cell line.

Published in:

Investigational New Drugs, 2013, v. 31, n. 2, p. 293, doi. 10.1007/s10637-012-9855-1

By:

Ekyalongo, Roudy;
Mukohara, Toru;
Kataoka, Yu;
Funakoshi, Yohei;
Tomioka, Hideo;
Kiyota, Naomi;
Fujiwara, Yutaka;
Minami, Hironobu

Publication type:

Article

Pre-operative chemoradiation followed by post-operative adjuvant therapy with tetrathiomolybdate, a novel copper chelator, for patients with resectable esophageal cancer.

Published in:

Investigational New Drugs, 2013, v. 31, n. 2, p. 435, doi. 10.1007/s10637-012-9864-0

By:

Schneider, Bryan;
Lee, Julia;
Hayman, James;
Chang, Andrew;
Orringer, Mark;
Pickens, Allan;
Pan, Charlie;
Merajver, Sofia;
Urba, Susan

Publication type:

Article

The non-genotoxic activator of the p53 pathway Nutlin-3 shifts the balance between E2F7 and E2F1 transcription factors in leukemic cells.

Published in:

2013

By:

di Iasio, Maria;
Zauli, Giorgio

Publication type:

Report

The inhibitor of Ca-dependent K channels TRAM-34 blocks growth of hepatocellular carcinoma cells via downregulation of estrogen receptor alpha mRNA and nuclear factor-kappaB.

Published in:

2013

By:

Freise, Christian;
Ruehl, Martin;
Seehofer, Daniel;
Hoyer, Joachim;
Somasundaram, Rajan

Publication type:

Report

A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2013, v. 31, n. 2, p. 409, doi. 10.1007/s10637-012-9904-9

By:

Gordon, Michael;
Mendelson, David;
Gross, Mitchell;
Uttenreuther-Fischer, Martina;
Ould-Kaci, Mahmoud;
Zhao, Yihua;
Stopfer, Peter;
Agus, David

Publication type:

Article

Inhibition of cancer growth and induction of apoptosis by BGP-13 and BGP-15, new calcipotriene-derived vitamin D analogs, in-vitro and in-vivo studies.

Published in:

Investigational New Drugs, 2013, v. 31, n. 2, p. 247, doi. 10.1007/s10637-012-9839-1

By:

Sintov, Amnon;
Berkovich, Liron;
Ben-Shabat, Shimon

Publication type:

Article

Gemcitabine alone and/or containing chemotherapy is efficient in refractory or relapsed NK/T-cell lymphoma.

Published in:

Investigational New Drugs, 2013, v. 31, n. 2, p. 469, doi. 10.1007/s10637-012-9889-4

By:

Ahn, Hee;
Kim, Seok;
Hwang, Deok;
Ko, Young;
Tang, Tiffany;
Lim, Soon;
Kim, Won

Publication type:

Article

Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma.

Published in:

Investigational New Drugs, 2013, v. 31, n. 2, p. 425, doi. 10.1007/s10637-012-9862-2

By:

Ott, Patrick;
Carvajal, Richard;
Pandit-Taskar, Neeta;
Jungbluth, Achim;
Hoffman, Eric;
Wu, Bor-Wen;
Bomalaski, John;
Venhaus, Ralph;
Pan, Linda;
Old, Lloyd;
Pavlick, Anna;
Wolchok, Jedd

Publication type:

Article

A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2013, v. 31, n. 2, p. 399, doi. 10.1007/s10637-012-9890-y

By:

Marshall, John;
Hwang, Jimmy;
Eskens, Ferry;
Burger, Herman;
Malik, Shakun;
Uttenreuther-Fischer, Martina;
Stopfer, Peter;
Ould-Kaci, Mahmoud;
Cohen, Roger;
Lewis, Nancy

Publication type:

Article

Erratum to: Inhibition of cancer growth and induction of apoptosis by BGP-13 and BGP-15, new calcipotriene-derived vitamin D analogs, in-vitro and in-vivo studies.

Published in:

2013

By:

Berkovich, Liron;
Sintov, Amnon;
Ben-Shabat, Shimon

Publication type:

Correction Notice

Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2013, v. 31, n. 2, p. 370, doi. 10.1007/s10637-012-9825-7

By:

Schwartz, Gary;
Carvajal, Richard;
Midgley, Rachel;
Rodig, Scott;
Stockman, Paul;
Ataman, Ozlem;
Wilson, David;
Das, Shampa;
Shapiro, Geoffrey

Publication type:

Article

Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer.

Published in:

Investigational New Drugs, 2013, v. 31, n. 2, p. 345, doi. 10.1007/s10637-012-9820-z

By:

Azad, Nilofer;
Dasari, Arvind;
Arcaroli, John;
Taylor, Gretchen;
Laheru, Daniel;
Carducci, Michael;
McManus, Martine;
Quackenbush, Kevin;
Wright, John;
Hidalgo, Manuel;
Diaz, Luis;
Donehower, Ross;
Zhao, Ming;
Rudek, Michelle;
Messersmith, Wells

Publication type:

Article

Population pharmacokinetic modeling of Sepantronium bromide (YM155), a small molecule survivin suppressant, in patients with non-small cell lung cancer, hormone refractory prostate cancer, or unresectable stage III or IV melanoma.

Published in:

Investigational New Drugs, 2013, v. 31, n. 2, p. 443, doi. 10.1007/s10637-012-9867-x

By:

Aoyama, Yumiko;
Kaibara, Atsunori;
Takada, Akitsugu;
Nishimura, Tetsuya;
Katashima, Masataka;
Sawamoto, Taiji

Publication type:

Article

Acknowledgement of Reviewers 2011.

Published in:: Investigational New Drugs, 2013, v. 31, n. 2, p. 491, doi. 10.1007/s10637-012-9905-8
Publication type:: Article

Vascular disrupting activity and the mechanism of action of EHT 6706, a novel anticancer tubulin polymerization inhibitor.

Published in:

Investigational New Drugs, 2013, v. 31, n. 2, p. 304, doi. 10.1007/s10637-012-9858-y

By:

Belzacq-Casagrande, Anne-Sophie;
Bachelot, Florence;
Oliveira, Catherine;
Coutadeur, Séverine;
Maurier-Mahé, Florence;
Throo, Emeline;
Chauvignac, Cédric;
Pognante, Laure;
Petibon, Angélique;
Taverne, Thierry;
Beausoleil, Eric;
Leblond, Bertrand;
Pando, Matthew;
Désiré, Laurent

Publication type:

Article

Efficacy of substituted 9-aminoacridine derivatives in small cell lung cancer.

Published in:

Investigational New Drugs, 2013, v. 31, n. 2, p. 285, doi. 10.1007/s10637-012-9854-2

By:

Ryan, Etchison;
Blake, A.;
Benoit, A.;
David, M.;
Robert, A.

Publication type:

Article

Inhibition of topoisomerase II α activity and induction of apoptosis in mammalian cells by semi-synthetic andrographolide analogues.

Published in:

Investigational New Drugs, 2013, v. 31, n. 2, p. 320, doi. 10.1007/s10637-012-9868-9

By:

Nateewattana, Jintapat;
Saeeng, Rungnapha;
Kasemsook, Sakkasem;
Suksen, Kanoknetr;
Dutta, Suman;
Jariyawat, Surawat;
Chairoungdua, Arthit;
Suksamrarn, Apichart;
Piyachaturawat, Pawinee

Publication type:

Article

Tumor regression with a combination of drugs interfering with the tumor metabolism: efficacy of hydroxycitrate, lipoic acid and capsaicin.

Published in:

Investigational New Drugs, 2013, v. 31, n. 2, p. 256, doi. 10.1007/s10637-012-9849-z

By:

Schwartz, Laurent;
Guais, Adeline;
Israël, Maurice;
Junod, Bernard;
Steyaert, Jean-Marc;
Crespi, Elisabetta;
Baronzio, Gianfranco;
Abolhassani, Mohammad

Publication type:

Article

Erratum to: Silymarin attenuated mast cell recruitment thereby decreased the expressions of matrix metalloproteinases-2 and 9 in rat liver carcinogenesis.

Published in:

2013

By:

Ramakrishnan, Gopalakrishnan;
Jagan, Sundaram;
Kamaraj, Sattu;
Anandakumar, Pandi;
Devaki, Thiruvengadam

Publication type:

Correction Notice

Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole.

Published in:

Investigational New Drugs, 2013, v. 31, n. 2, p. 381, doi. 10.1007/s10637-012-9829-3

By:

Devriese, L.;
Mergui-Roelvink, M.;
Wanders, J.;
Jenner, A.;
Edwards, G.;
Reyderman, L.;
Copalu, W.;
Peng, F.;
Marchetti, S.;
Beijnen, J.;
Schellens, J.

Publication type:

Article

Clinical trial design in biosimilar drug development.

Published in:

Investigational New Drugs, 2013, v. 31, n. 2, p. 479, doi. 10.1007/s10637-012-9899-2

By:

Dranitsaris, G.;
Dorward, K.;
Hatzimichael, E.;
Amir, E.

Publication type:

Article

The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines.

Published in:

2013

By:

Davidson, David;
Wang, Yunzhe;
Aloyz, Raquel;
Panasci, Lawrence

Publication type:

Report

The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft models.

Published in:

Investigational New Drugs, 2013, v. 31, n. 2, p. 273, doi. 10.1007/s10637-012-9852-4

By:

Clémenson, Céline;
Jouannot, Erwan;
Merino-Trigo, Ana;
Rubin-Carrez, Chantal;
Deutsch, Eric

Publication type:

Article